10-K: GRAIL, Inc. Navigates Cancer Detection Market with FDA Submission Planned for 2026

GRAIL, Inc. aims to revolutionize early cancer detection with its Galleri test, targeting FDA approval in 2026 and expanding commercial partnerships.

Summary

• GRAIL, Inc. is focused on early cancer detection through its Galleri test, a multi-cancer early detection (MCED) screening test.
• The company plans to submit a premarket approval application (PMA) to the FDA in the first half of 2026, supported by data from the NHS-Galleri Trial and PATHFINDER 2 study.
• As of December 31, 2024, GRAIL has sold over 290,000 commercial Galleri tests, including more than 137,000 in 2024, and has established partnerships with healthcare systems, employers, payors, and life insurance providers.
• The company estimates that adding Galleri to standard cancer screenings could potentially avert approximately 100,000 cancer deaths per year in the United States.
• GRAIL is also developing a precision oncology portfolio, including a research-use-only (RUO) targeted methylation platform, and has partnered with oncology therapeutics companies.
• The company is collecting population-scale clinical data from more than 385,000 participants across nine clinical studies.
• GRAIL reported a net loss of $2.0 billion for fiscal year 2024, which includes $1.4 billion of goodwill and intangible assets impairment.
• The company believes its existing cash and cash equivalents, and short-term marketable securities will be sufficient to fund its projected operations for at least the next 12 months.
• A restructuring plan was implemented to focus on the core MCED business and reduce overall spend, with expected annual cost savings of approximately $120 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in commercialization and clinical validation, significant net losses and reliance on future FDA approval create uncertainty.

Positives

• Galleri has demonstrated a high positive predictive value and a low false positive rate in clinical studies.
• The company has established commercial partnerships with leading healthcare systems, employers, payors, and life insurance providers.
• GRAIL is working with NHS England, which could facilitate adoption in other single-payor systems.
• The company has a highly-differentiated methylation platform that enables product opportunities across the cancer care continuum.
• GRAIL has a highly experienced and multidisciplinary team.
• The company has a strong intellectual property portfolio.
• The company has a patient-first corporate culture that attracts top talent.

Negatives

• GRAIL has incurred significant net losses in each period since its inception and anticipates that it will continue to incur net losses for the coming years.
• Galleri has not been approved or cleared by the FDA.
• The company is highly dependent on Galleri for its success.
• The company may not be able to generate sufficient revenue to offset its ongoing operating expenses and achieve and maintain profitability.
• The company relies on sole suppliers for key materials.
• The company could have an indemnification obligation to Illumina if the Distribution were determined not to qualify for non-recognition treatment for U.S. federal tax purposes.
• The company has agreed to numerous restrictions to preserve the non-recognition treatment of the Spin-Off, which may reduce its strategic and operating flexibility.

Risks

• The company operates in a rapidly evolving field and has a limited operating history.
• The clinical study process is lengthy and expensive with uncertain outcomes.
• If the company fails to obtain additional financing, it may be unable to expand its commercialization efforts or develop additional products.
• If the company's products result in direct or indirect participant or patient harm or injury, it could be subject to significant reputational and liability risks.
• The company's information technology systems may fail or suffer cybersecurity incidents or cyberattacks.
• The company's quarterly results of operations may fluctuate significantly.
• The company may be unable to obtain and maintain intellectual property protection for its technology.
• The company could have an indemnification obligation to Illumina if the Distribution were determined not to qualify for non-recognition treatment for U.S. federal tax purposes.
• The company has agreed to numerous restrictions to preserve the non-recognition treatment of the Spin-Off, which may reduce its strategic and operating flexibility.

Future Outlook

GRAIL plans to pursue FDA approval for Galleri and is working with stakeholders to advance and shape the public reimbursement landscape. The company expects to continue to incur operating losses as it invests in research and development and commercialization of existing products.

Management Comments

• The NHS will evaluate the final results from the NHS-Galleri Trial, which are expected to be available in 2026, before determining whether to implement the Galleri test in the NHS.
• We believe the decision will include considerations such as NHS budget, political priorities, cost-effectiveness and implementation constraints in addition to an evaluation of the final results.

Industry Context

The multi-cancer early detection (MCED) market is competitive, with several companies developing similar tests. GRAIL believes it is differentiated by its robust intellectual property portfolio, extensive research, rigorous and objective approach, and multidisciplinary capabilities.

Comparison to Industry Standards

• Several companies, including Adela, Inc., Clearnote Health, DELFI Diagnostics, Inc., Exact Sciences Corporation, Freenome Inc., Guardant Health, Inc., Harbinger Health and Natera, Inc. are developing tests to detect certain types of cancer early.
• Guardant Health, Inc., Exact Sciences Corporation, and Natera, Inc. have announced intentions to develop or launch multi-cancer early detection products.
• Unlike with respect to MCED testing, precision oncology is a very competitive space with many industry participants such as Roche/Foundation Medicine, Inc., Natera, Inc., Guardant, Inc., Tempus AI, Inc., Clearnote Health, NeoGenomics Laboratories, Personalis, Inc., Twist Bioscience Corp. and Adaptive Biotechnologies Corp.

Legal Proceedings

• The company is involved in various lawsuits and claims arising in the ordinary course of business.
• The company is cooperating with the SEC in an investigation relating to Illumina's acquisition of GRAIL and certain statements and disclosures concerning GRAIL, its products and the acquisition, and related to the conduct and compensation of certain members of Illumina and GRAIL management, among other things.
• The company is a defendant in a securities class action lawsuit alleging materially false and misleading statements and omissions relating to Illumina's acquisition of GRAIL.

Related Party Transactions

• The company has entered into a supply and commercialization agreement with Illumina, which includes a royalty payment obligation.
• The company received a cash contribution of $932.3 million from Illumina in connection with the Spin-Off.
• The company has entered into a Tax Matters Agreement with Illumina to govern the respective rights, responsibilities and obligations of Illumina and the Company after the Spin-Off with respect to all tax matters and will include restrictions to preserve the tax-free status of the Distribution.
• The company has entered into an Employee Matters Agreement with Illumina to address employment, compensation, and benefits matters, including the allocation and treatment of assets and liabilities relating to employees and compensation and benefits plans and programs in which GRAIL employees participate, as well as the treatment of cash-based incentive awards in connection with the Spin-Off.
• The company has entered into a Stockholder and Registration Rights Agreement with Illumina, pursuant to which we provide Illumina registration rights with respect to the shares of our common stock it retained following the Spin-Off.

Stakeholder Impact

• Shareholders may experience fluctuations in the stock price due to market conditions, company performance, and regulatory developments.
• Employees may be affected by the restructuring plan and changes in compensation and benefits.
• Patients may benefit from increased access to early cancer detection through Galleri.
• Healthcare providers may have new tools and guidelines for cancer screening and diagnosis.
• Payors may face new coverage and reimbursement decisions related to MCED tests.

Next Steps

• Complete a premarket approval application (PMA) submission with the FDA in the first half of 2026.
• Continue working with NHS England to complete the NHS-Galleri Trial.
• Continue to invest in clinical evidence generation and work with regulatory bodies and payors to expand coverage for early cancer screening.
• Continue to improve technologies and launch innovative products across the cancer care continuum.

Key Dates

Keywords

Galleri, cancer detection, FDA, MCED, clinical trials, methylation platform, reimbursement, Illumina, Spin-Off, Medicare, NHS, intellectual property, precision oncology, regulatory approval, early detection